首页 > 最新文献

JCO Global Oncology最新文献

英文 中文
Erratum: Factors Affecting Breast Cancer Screening in Ukraine. 勘误:影响乌克兰乳腺癌筛查的因素。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.1200/GO-24-00447
{"title":"Erratum: Factors Affecting Breast Cancer Screening in Ukraine.","authors":"","doi":"10.1200/GO-24-00447","DOIUrl":"https://doi.org/10.1200/GO-24-00447","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400447"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic Landscape in Prostate Cancer in a Latin American Population. 拉丁美洲人群中的前列腺癌基因组图谱。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.1200/GO.24.00072
Martín Angel, Berenice Freile, Andres Rodriguez, Federico Cayol, Ray Manneh Kopp, Patricia Rioja, Tomas Soule, Federico Losco, Laura Bernal Vaca, Jose Mauricio Penaloza, Maycos Leandro Zapata Muñoz, Silvia Patricia Neciosup, Roger Rodrigo Sanchez, Carolina Passarella, Elvio Guerreño, Diego Farelluk, Ernesto Maturana Leiva, Martin Zarba, Maria Teresa Bourlon, Mauricio Mora Pineda, Juan Pablo Sade

Purpose: This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC).

Patients and methods: This study is a retrospective, multicenter cohort study of patients with mPC and reports on genomic testing. Patients were included from 12 academic centers in five countries.

Results: A total of 349 patients with PC were included in this study. Most patients (209, 59.9%) were de novo metastatic. Genomic analysis was performed in 233 (66.6%) patients in the metastatic castration-resistant prostate cancer (mCRPC) setting, and only 115 (32.8%) patients had a tumor evaluation in the metastatic hormone sensitive prostate cancer scenario. The evaluation of somatic and/or germline mutations was performed through multigene panel analyses in 290 (83.09%) patients, and next-generation sequencing of BRCA1 and BRCA2 genes was performed in 59 (16.91%) patients. Analyzing the mCRPC subgroup, with a median follow-up of 15.6 months (IQR, 14-19.06), the median progression-free survival (PFS) was not reached (NR) and the PFS at 16 months was 58.7% (95% CI, 50.8 to 67.8). When comparing patients with BRCA mutations with those who are not BRCA-mutated in the mCRPC scenario, the median PFS was NR (95% CI, 14 to NR) and 26.3 months (95% CI, 16.7 to 36.5; P = .2), respectively. Two of six patients with BRCA mutations were treated with targeted therapies (poly-ADP-ribose polymerase inhibitors).

Conclusion: Our study, to the best of our knowledge, represents one of the larger data sets for somatic testing in patients with PC in Latin America (LATAM). It adds valuable information to the growing body of knowledge about the genomic landscape of advanced PC in real-world daily practice scenarios in LATAM countries, which are not always well-represented in large-scale randomized clinical trials.

目的:本研究旨在描述转移性前列腺癌(mPC)患者的基因组特征:本研究是一项针对mPC患者的回顾性多中心队列研究,并报告了基因组检测结果。患者来自五个国家的12个学术中心:本研究共纳入了 349 名 PC 患者。大多数患者(209人,占59.9%)为新发转移灶。233例(66.6%)转移性去势抵抗性前列腺癌(mCRPC)患者进行了基因组分析,只有115例(32.8%)转移性激素敏感性前列腺癌患者进行了肿瘤评估。290例(83.09%)患者通过多基因面板分析进行了体细胞和/或种系突变评估,59例(16.91%)患者进行了BRCA1和BRCA2基因的新一代测序。分析mCRPC亚组,中位随访时间为15.6个月(IQR,14-19.06),中位无进展生存期(PFS)未达到(NR),16个月时的PFS为58.7%(95% CI,50.8-67.8)。在mCRPC方案中,将BRCA突变患者与未发生BRCA突变的患者进行比较,中位PFS分别为NR(95% CI,14至NR)和26.3个月(95% CI,16.7至36.5;P = .2)。6名BRCA突变患者中有2名接受了靶向治疗(聚ADP核糖聚合酶抑制剂):据我们所知,我们的研究代表了拉丁美洲(LATAM)PC 患者体细胞检测的较大数据集之一。它为拉丁美洲和加勒比海地区国家日益增长的有关晚期 PC 基因组情况的知识库增添了宝贵的信息,而这些国家在大规模随机临床试验中的代表性并不总是很强。
{"title":"Genomic Landscape in Prostate Cancer in a Latin American Population.","authors":"Martín Angel, Berenice Freile, Andres Rodriguez, Federico Cayol, Ray Manneh Kopp, Patricia Rioja, Tomas Soule, Federico Losco, Laura Bernal Vaca, Jose Mauricio Penaloza, Maycos Leandro Zapata Muñoz, Silvia Patricia Neciosup, Roger Rodrigo Sanchez, Carolina Passarella, Elvio Guerreño, Diego Farelluk, Ernesto Maturana Leiva, Martin Zarba, Maria Teresa Bourlon, Mauricio Mora Pineda, Juan Pablo Sade","doi":"10.1200/GO.24.00072","DOIUrl":"10.1200/GO.24.00072","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC).</p><p><strong>Patients and methods: </strong>This study is a retrospective, multicenter cohort study of patients with mPC and reports on genomic testing. Patients were included from 12 academic centers in five countries.</p><p><strong>Results: </strong>A total of 349 patients with PC were included in this study. Most patients (209, 59.9%) were de novo metastatic. Genomic analysis was performed in 233 (66.6%) patients in the metastatic castration-resistant prostate cancer (mCRPC) setting, and only 115 (32.8%) patients had a tumor evaluation in the metastatic hormone sensitive prostate cancer scenario. The evaluation of somatic and/or germline mutations was performed through multigene panel analyses in 290 (83.09%) patients, and next-generation sequencing of <i>BRCA1</i> and <i>BRCA2</i> genes was performed in 59 (16.91%) patients. Analyzing the mCRPC subgroup, with a median follow-up of 15.6 months (IQR, 14-19.06), the median progression-free survival (PFS) was not reached (NR) and the PFS at 16 months was 58.7% (95% CI, 50.8 to 67.8). When comparing patients with <i>BRCA</i> mutations with those who are not <i>BRCA</i>-mutated in the mCRPC scenario, the median PFS was NR (95% CI, 14 to NR) and 26.3 months (95% CI, 16.7 to 36.5; <i>P</i> = .2), respectively. Two of six patients with <i>BRCA</i> mutations were treated with targeted therapies (poly-ADP-ribose polymerase inhibitors).</p><p><strong>Conclusion: </strong>Our study, to the best of our knowledge, represents one of the larger data sets for somatic testing in patients with PC in Latin America (LATAM). It adds valuable information to the growing body of knowledge about the genomic landscape of advanced PC in real-world daily practice scenarios in LATAM countries, which are not always well-represented in large-scale randomized clinical trials.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400072"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Dietary Patterns and Risk of Breast Cancer in Africa: A Systematic Review. 勘误:非洲饮食模式与乳腺癌风险:系统回顾。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.1200/GO-24-00405
{"title":"Erratum: Dietary Patterns and Risk of Breast Cancer in Africa: A Systematic Review.","authors":"","doi":"10.1200/GO-24-00405","DOIUrl":"https://doi.org/10.1200/GO-24-00405","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400405"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142143068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to S. Najem et al. 对 S. Najem 等人的答复
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.1200/GO-24-00331
Khalid El Bairi, Dario Trapani

The emergence of predatory oncology journals represents a significant threat to research integrity. Distance-education approaches to inform oncologists about this risk is promising and effective, particularly for LMICs, as it offers flexibility and affordability.

掠夺性肿瘤学期刊的出现对研究诚信构成重大威胁。采用远程教育方法让肿瘤学家了解这一风险是很有前途和有效的,尤其是对低收入国家而言,因为这种方法既灵活又经济实惠。
{"title":"Reply to S. Najem et al.","authors":"Khalid El Bairi, Dario Trapani","doi":"10.1200/GO-24-00331","DOIUrl":"https://doi.org/10.1200/GO-24-00331","url":null,"abstract":"<p><p>The emergence of predatory oncology journals represents a significant threat to research integrity. Distance-education approaches to inform oncologists about this risk is promising and effective, particularly for LMICs, as it offers flexibility and affordability.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400331"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. 台湾非小细胞肺癌基因变异的全面新一代测序登记:真实世界队列研究-台湾肿瘤合作组织 T1521。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.1200/GO.24.00125
Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Yang

Purpose: Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis.

Materials and methods: We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor (EGFR) mutations or anaplastic large-cell lymphoma kinase (ALK) rearrangement-positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) EGFR-/ALK-negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment. These patients were divided into five cohorts. Comprehensive tissue-based NGS testing (ACTOnco+) was conducted.

Results: Cohort 1: EGFR TKI-pretreated EGFR-mutated population (50.0%, n = 250), cohort 2: ALK inhibitor-pretreated ALK-positive population (1.6%, n = 8), cohort 3: treatment-naïve EGFR-/ALK-negative population (28.2%, n = 141), cohort 4: pretreated EGFR-/ALK-negative population (16.8%, n = 84), and cohort 5: squamous cell carcinoma (3.4%, n = 17). In cohort 1, 11.2% (28/250) of the patients had MET amplification, 32.4% (81/250) had been treated with osimertinib, and EGFR C797S was detected in 6.2% (5/81) of these patients. In cohort 2, resistance ALK mutation was detected in 37.5% (3/8) of the patients. In cohorts 3 and 4, targetable genetic alterations, including EGFR mutation (13.3%), ERBB2 mutation (9.3%), MET exon 14 skipping (5.3%), KRAS G12C mutation (4.4%), ROS1 fusion (2.7%), RET fusion (1.8%), and BRAF V600E mutation (1.3%), were detected. In cohort 5, MET exon 14 skipping was detected in 29.4% (5/17) of the patients.

Conclusion: This multicenter registration study investigated tissue-based NGS for a specific patient population with NSCLC in Taiwan.

目的:基于组织的新一代测序(NGS)分析被强烈推荐用于晚期/转移性非小细胞肺癌(NSCLC)患者。我们对需要进行基于组织的 NGS 分析的特定 NSCLC 患者群体进行了调查:我们招募了 500 名晚期/转移性(1)表皮生长因子受体(EGFR)突变或无性大细胞淋巴瘤激酶(ALK)重排阳性的 NSCLC 患者,这些患者至少接受过一次酪氨酸激酶抑制剂(TKI)治疗失败;(2)EGFR/ALK 阴性的非鳞癌患者;(3)非吸烟或轻度吸烟的鳞癌 NSCLC 患者,这些患者未经治疗或至少接受过两次系统治疗失败。这些患者被分为五个队列。进行了基于组织的全面 NGS 检测(ACTOnco+):队列 1:经 EGFR TKI 治疗的 EGFR 突变人群(50.0%,n = 250);队列 2:经 ALK 抑制剂治疗的 ALK 阳性人群(1.6%,n = 8);队列 3:治疗无效的 EGFR-/ALK 阴性人群(28.2%,n = 141),队列 4:EGFR-/ALK 阴性预处理人群(16.8%,n = 84),队列 5:鳞癌(3.4%,n = 17)。在队列 1 中,11.2%(28/250)的患者有 MET 扩增,32.4%(81/250)的患者接受过奥希替尼治疗,其中 6.2%(5/81)的患者检测到表皮生长因子受体 C797S。在队列 2 中,37.5%(3/8)的患者检测到耐药性 ALK 突变。在队列 3 和队列 4 中,检测到了可靶向的基因改变,包括表皮生长因子受体突变(13.3%)、ERBB2 突变(9.3%)、MET 14 号外显子跳越(5.3%)、KRAS G12C 突变(4.4%)、ROS1 融合(2.7%)、RET 融合(1.8%)和 BRAF V600E 突变(1.3%)。在队列 5 中,29.4% 的患者(5/17)检测到 MET 14 号外显子跳变:这项多中心登记研究调查了台湾特定 NSCLC 患者群体中基于组织的 NGS。
{"title":"Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.","authors":"Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Yang","doi":"10.1200/GO.24.00125","DOIUrl":"10.1200/GO.24.00125","url":null,"abstract":"<p><strong>Purpose: </strong>Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis.</p><p><strong>Materials and methods: </strong>We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor (<i>EGFR</i>) mutations or anaplastic large-cell lymphoma kinase (<i>ALK</i>) rearrangement-positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) <i>EGFR-/ALK</i>-negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment. These patients were divided into five cohorts. Comprehensive tissue-based NGS testing (ACTOnco+) was conducted.</p><p><strong>Results: </strong>Cohort 1: EGFR TKI-pretreated <i>EGFR</i>-mutated population (50.0%, n = 250), cohort 2: ALK inhibitor-pretreated <i>ALK</i>-positive population (1.6%, n = 8), cohort 3: treatment-naïve <i>EGFR-/ALK</i>-negative population (28.2%, n = 141), cohort 4: pretreated <i>EGFR-/ALK</i>-negative population (16.8%, n = 84), and cohort 5: squamous cell carcinoma (3.4%, n = 17). In cohort 1, 11.2% (28/250) of the patients had <i>MET</i> amplification, 32.4% (81/250) had been treated with osimertinib, and <i>EGFR</i> C797S was detected in 6.2% (5/81) of these patients. In cohort 2, resistance ALK mutation was detected in 37.5% (3/8) of the patients. In cohorts 3 and 4, targetable genetic alterations, including <i>EGFR</i> mutation (13.3%), <i>ERBB2</i> mutation (9.3%), <i>MET</i> exon 14 skipping (5.3%), <i>KRAS</i> G12C mutation (4.4%), <i>ROS1</i> fusion (2.7%), <i>RET</i> fusion (1.8%), and <i>BRAF</i> V600E mutation (1.3%), were detected. In cohort 5, <i>MET</i> exon 14 skipping was detected in 29.4% (5/17) of the patients.</p><p><strong>Conclusion: </strong>This multicenter registration study investigated tissue-based NGS for a specific patient population with NSCLC in Taiwan.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400125"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East. 全面分析转移性前列腺癌:来自中东的真实世界数据。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.1200/GO.24.00042
Ramiz Abu-Hijlih, Samer Salah, Haneen Abaza, Ayat Taqash, Hadeel Abdelkhaleq, Akram Al-Ibraheem, Amal Al-Omari

Purpose: Metastatic prostate cancer (Pca) is a complex disease with diverse clinical characteristics and outcomes across the geographical distribution. Herein, we present a series of patients from the Middle East, aiming at identifying disease outcomes and prognostic factors specific to this regional context.

Methods and materials: This is a retrospective study of patients with metastatic Pca, diagnosed at King Hussein Cancer Center, Jordan, between 2006 and 2018. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Factors that significantly affected overall survival (OS) in the univariable analysis were examined in a multivariable Cox regression analysis.

Results: A total of 188 patients with metastatic Pca were included in this analysis, of whom 168 (89%) had de novo metastatic disease. The median age at diagnosis was 68 years, 144 (77%) had bone metastasis, 32 (17%) had visceral metastasis, and 126 (67%) had high-volume disease. At a median follow-up of 67 months, the median OS was 44.3 months. The following factors predicted inferior OS in univariable analysis: smoking, normal BMI, high-volume disease, high alkaline phosphatase (ALP), previous local therapy for prostate, and orchiectomy versus medical androgen deprivation therapy (ADT). On multivariable analysis, high-volume disease (hazard ratio [HR], 1.92 [95% CI, 1.17 to 3.13]; P = .0094), high ALP (HR, 2.136 [95% CI, 1.38 to 3.31]; P < .001), and orchiectomy (HR, 2.40 [95% CI, 1.51 to 3.82]; P < .001) emerged as independent factors for inferior OS.

Conclusion: Metastatic Pca outcomes in our population closely align with the global benchmark. High volume status, elevated ALP, and performance of surgical as opposed to medical ADT emerge as prognostic indicators of poor survival.

目的:转移性前列腺癌(Pca)是一种复杂的疾病,其临床特征和预后因地域分布而各不相同。在此,我们介绍了一系列来自中东地区的患者,旨在确定该地区特有的疾病结果和预后因素:这是一项回顾性研究,研究对象为2006年至2018年间在约旦侯赛因国王癌症中心确诊的转移性肺癌患者。采用卡普兰-梅耶法估算生存率,并用对数秩检验进行比较。在单变量分析中对总生存率(OS)有明显影响的因素在多变量考克斯回归分析中进行了研究:共有188名转移性肺结核患者参与了此次分析,其中168人(89%)患有新发转移性疾病。诊断时的中位年龄为68岁,144人(77%)有骨转移,32人(17%)有内脏转移,126人(67%)有高体积疾病。中位随访时间为67个月,中位OS为44.3个月。在单变量分析中,以下因素预示着较差的OS:吸烟、体重指数正常、高体积疾病、高碱性磷酸酶(ALP)、既往接受过前列腺局部治疗以及睾丸切除术与药物雄激素剥夺疗法(ADT)。在多变量分析中,高体积疾病(危险比 [HR],1.92 [95% CI,1.17 至 3.13];P = .0094)、高 ALP(HR,2.136 [95% CI,1.38 至 3.31];P .001)和睾丸切除术(HR,2.40 [95% CI,1.51 至 3.82];P .001)是导致较差 OS 的独立因素:结论:我国人群的转移性白血病预后与全球基准非常接近。高血容量状态、ALP升高、手术而非药物ADT是预后不良的生存指标。
{"title":"Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East.","authors":"Ramiz Abu-Hijlih, Samer Salah, Haneen Abaza, Ayat Taqash, Hadeel Abdelkhaleq, Akram Al-Ibraheem, Amal Al-Omari","doi":"10.1200/GO.24.00042","DOIUrl":"https://doi.org/10.1200/GO.24.00042","url":null,"abstract":"<p><strong>Purpose: </strong>Metastatic prostate cancer (Pca) is a complex disease with diverse clinical characteristics and outcomes across the geographical distribution. Herein, we present a series of patients from the Middle East, aiming at identifying disease outcomes and prognostic factors specific to this regional context.</p><p><strong>Methods and materials: </strong>This is a retrospective study of patients with metastatic Pca, diagnosed at King Hussein Cancer Center, Jordan, between 2006 and 2018. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Factors that significantly affected overall survival (OS) in the univariable analysis were examined in a multivariable Cox regression analysis.</p><p><strong>Results: </strong>A total of 188 patients with metastatic Pca were included in this analysis, of whom 168 (89%) had de novo metastatic disease. The median age at diagnosis was 68 years, 144 (77%) had bone metastasis, 32 (17%) had visceral metastasis, and 126 (67%) had high-volume disease. At a median follow-up of 67 months, the median OS was 44.3 months. The following factors predicted inferior OS in univariable analysis: smoking, normal BMI, high-volume disease, high alkaline phosphatase (ALP), previous local therapy for prostate, and orchiectomy versus medical androgen deprivation therapy (ADT). On multivariable analysis, high-volume disease (hazard ratio [HR], 1.92 [95% CI, 1.17 to 3.13]; <i>P =</i> .0094), high ALP (HR, 2.136 [95% CI, 1.38 to 3.31]; <i>P <</i> .001), and orchiectomy (HR, 2.40 [95% CI, 1.51 to 3.82]; <i>P <</i> .001) emerged as independent factors for inferior OS.</p><p><strong>Conclusion: </strong>Metastatic Pca outcomes in our population closely align with the global benchmark. High volume status, elevated ALP, and performance of surgical as opposed to medical ADT emerge as prognostic indicators of poor survival.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400042"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents. COVID-19 大流行早期阶段对两大洲综合癌症中心结直肠癌和肛门癌治疗质量的影响。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.1200/GO.24.00037
Erick F Saldanha, Melanie Powis, Divya Sharma, Osvaldo Espin-Garcia, Saidah Hack, Felicia Cavalher, Maria Rita Costa, Maria Simoes, Huaqi Li, Abed Baiad, Kevin Chen, Zuhul Mohmand, Peter Nakhla, Samuel Aguiar, Rachel Riechelmann, Monika K Krzyzanowska

Purpose: The early phase of the COVID-19 pandemic affected cancer care globally. Evaluating the impact of the pandemic on the quality of cancer care delivery is crucial for understanding how changes in care delivery may influence outcomes. Our study compared care delivered during the early phase of the pandemic with the same period in the previous year at two institutions across continents (Princess Margaret Cancer Center [PM] in Canada and A.C. Camargo Cancer Center [AC] in Brazil).

Methods: Patients newly diagnosed with colorectal or anal cancer between February and December 2019 and the same period in 2020 were analyzed. Sociodemographic and clinical characteristics and performance of individual indicators within and between centers and between the peri-COVID-19 and control cohorts were tested using Cohen's h test to assess the standardized differences between the two groups.

Results: Among 925 patients, distinct effects of the early COVID-19 pandemic on oncology services were observed. AC experienced a 50% reduction in patient consultations (98 v 197) versus a 12.5% reduction at PM (294 v 336). Similarly, AC experienced a higher proportion of stage IV disease presentations (42.9% v 29.9%; P = .015) and an increase in treatment delay (61.9% v 9.7%; P < .001) compared with prepandemic. At PM, a 10% increase in treatment interruption (32.4% v 22.3%; P < .001) and a higher rate of discontinuation of radiotherapy (9.4% v 1.1%; P < .001) were observed during the pandemic. Postsurgical readmission rates increased in both AC (20.9% v 2.6%; P < .001) and PM (10.5% v 3.6%; P < .01).

Conclusion: The early phase of the COVID-19 pandemic affected the quality of care delivery for colorectal and anal cancers at both centers. However, the magnitude of this impact was greater in Brazil.

目的:COVID-19 大流行的早期阶段影响了全球的癌症治疗。评估大流行对癌症护理服务质量的影响对于了解护理服务的变化如何影响治疗效果至关重要。我们的研究比较了各大洲两家机构(加拿大玛格丽特公主癌症中心[PM]和巴西 A.C. Camargo 癌症中心[AC])在大流行早期和前一年同期提供的医疗服务:方法:对2019年2月至12月期间和2020年同期新确诊的结直肠癌或肛门癌患者进行分析。采用 Cohen's h 检验法检测了各中心内部、中心之间以及围 COVID-19 和对照组之间的社会人口学和临床特征以及各项指标的表现,以评估两组之间的标准化差异:结果:在 925 名患者中,观察到了 COVID-19 大流行早期对肿瘤服务的明显影响。AC 组的患者就诊人数减少了 50%(98 对 197),而 PM 组减少了 12.5%(294 对 336)。同样,与大流行前相比,AC 的 IV 期病例比例更高(42.9% 对 29.9%;P = .015),治疗延迟率增加(61.9% 对 9.7%;P < .001)。在下午,大流行期间观察到的治疗中断率增加了 10%(32.4% 对 22.3%;P < .001),放疗中断率增加了 10%(9.4% 对 1.1%;P < .001)。AC(20.9% 对 2.6%;P < .001)和 PM(10.5% 对 3.6%;P < .01)的手术后再入院率均有所上升:结论:COVID-19大流行的早期阶段影响了两个中心的结直肠癌和肛门癌治疗质量。然而,巴西受到的影响更大。
{"title":"Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents.","authors":"Erick F Saldanha, Melanie Powis, Divya Sharma, Osvaldo Espin-Garcia, Saidah Hack, Felicia Cavalher, Maria Rita Costa, Maria Simoes, Huaqi Li, Abed Baiad, Kevin Chen, Zuhul Mohmand, Peter Nakhla, Samuel Aguiar, Rachel Riechelmann, Monika K Krzyzanowska","doi":"10.1200/GO.24.00037","DOIUrl":"10.1200/GO.24.00037","url":null,"abstract":"<p><strong>Purpose: </strong>The early phase of the COVID-19 pandemic affected cancer care globally. Evaluating the impact of the pandemic on the quality of cancer care delivery is crucial for understanding how changes in care delivery may influence outcomes. Our study compared care delivered during the early phase of the pandemic with the same period in the previous year at two institutions across continents (Princess Margaret Cancer Center [PM] in Canada and A.C. Camargo Cancer Center [AC] in Brazil).</p><p><strong>Methods: </strong>Patients newly diagnosed with colorectal or anal cancer between February and December 2019 and the same period in 2020 were analyzed. Sociodemographic and clinical characteristics and performance of individual indicators within and between centers and between the peri-COVID-19 and control cohorts were tested using Cohen's <i>h</i> test to assess the standardized differences between the two groups.</p><p><strong>Results: </strong>Among 925 patients, distinct effects of the early COVID-19 pandemic on oncology services were observed. AC experienced a 50% reduction in patient consultations (98 <i>v</i> 197) versus a 12.5% reduction at PM (294 <i>v</i> 336). Similarly, AC experienced a higher proportion of stage IV disease presentations (42.9% <i>v</i> 29.9%; <i>P</i> = .015) and an increase in treatment delay (61.9% <i>v</i> 9.7%; <i>P</i> < .001) compared with prepandemic. At PM, a 10% increase in treatment interruption (32.4% <i>v</i> 22.3%; <i>P</i> < .001) and a higher rate of discontinuation of radiotherapy (9.4% <i>v</i> 1.1%; <i>P</i> < .001) were observed during the pandemic. Postsurgical readmission rates increased in both AC (20.9% <i>v</i> 2.6%; <i>P</i> < .001) and PM (10.5% <i>v</i> 3.6%; <i>P</i> < .01).</p><p><strong>Conclusion: </strong>The early phase of the COVID-19 pandemic affected the quality of care delivery for colorectal and anal cancers at both centers. However, the magnitude of this impact was greater in Brazil.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400037"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States. 基于抗-PD(L)1的联合疗法一线治疗非鳞状转移性非小细胞肺癌的实际效果:欧洲、日本和美国的多区域病历回顾。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 DOI: 10.1200/GO.24.00138
Stephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Fabrice Barlesi, Ticiana A Leal

Purpose: Anti-PD-1/PD(L)1-based combination therapy is the standard of care in first line (1L) for metastatic nonsquamous non-small cell lung cancer (mnsqNSCLC) without driver alterations. This study aimed to evaluate real-world clinical outcomes in this population.

Methods: Eligible physicians in the United States, Europe, and Japan abstracted information from medical charts of eligible adult patients with mnsqNSCLC (without EGFR/ALK, no known ROS1 alterations) who initiated 1L anti-PD(L)1-based combination therapy for mnsqNSCLC between 2017 and 2021. Kaplan-Meier analyses were used to assess overall survival (OS), time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after 1L initiation.

Results: Overall, 142 physicians contributed deidentified data from 430 patients' medical charts. The distribution of PD-L1 expression levels was 31.2% with tumor proportion score (TPS) <1%, 42.3% with TPS 1%-49%, and 26.5% with TPS ≥50%. In 1L, patients received anti-PD(L)1 + chemotherapy (84.6%), anti-PD(L)1 + anti-CTLA4 with or without chemotherapy (11.9%), and anti-PD(L)1 + chemotherapy + anti-vascular endothelial growth factor receptor (3.5%). The median OS was 21.7 months (TPS <1%: 18.3 months; TPS 1%-49%: 21.6 months; TPS ≥50%: 24.0 months). The median TTD was 11.0 months (TPS <1%: 9.1 months; TPS 1%-49%: 10.9 months; TPS ≥50%: 12.2 months). The median rwPFS was 11.2 months (TPS <1%: 9.3 months; TPS 1%-49%: 11.1 months; TPS ≥50%: 13.2 months).

Conclusion: This study assessed the real-world clinical effectiveness of 1L anti-PD(L)1-based combination therapy for mnsqNSCLC. Results from this study were generally consistent with previous clinical trials and published real-world evidence in 1L mnsqNSCLC.

目的:基于抗PD-1/PD(L)1的联合疗法是治疗无驱动基因改变的转移性非鳞状非小细胞肺癌(mnsqNSCLC)一线(1L)治疗的标准疗法。本研究旨在评估这一人群的实际临床疗效:美国、欧洲和日本的合格医生从符合条件的mnsqNSCLC(无表皮生长因子受体/ALK,无已知ROS1改变)成年患者的病历中抽取了信息,这些患者在2017年至2021年期间开始接受基于1L抗PD(L)1的mnsqNSCLC联合治疗。卡普兰-梅耶分析用于评估1L疗法启动后的总生存期(OS)、终止治疗时间(TTD)和实际无进展生存期(rwPFS):共有142名医生提供了430名患者病历中的去标识化数据。PD-L1表达水平与肿瘤比例评分(TPS)的分布为31.2%:本研究评估了基于 1L 抗 PD(L)1 联合疗法治疗 mnsqNSCLC 的实际临床疗效。本研究的结果与之前的临床试验和已发表的 1L mnsqNSCLC 真实世界证据基本一致。
{"title":"Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States.","authors":"Stephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Fabrice Barlesi, Ticiana A Leal","doi":"10.1200/GO.24.00138","DOIUrl":"https://doi.org/10.1200/GO.24.00138","url":null,"abstract":"<p><strong>Purpose: </strong>Anti-PD-1/PD(L)1-based combination therapy is the standard of care in first line (1L) for metastatic nonsquamous non-small cell lung cancer (mnsqNSCLC) without driver alterations. This study aimed to evaluate real-world clinical outcomes in this population.</p><p><strong>Methods: </strong>Eligible physicians in the United States, Europe, and Japan abstracted information from medical charts of eligible adult patients with mnsqNSCLC (without <i>EGFR</i>/<i>ALK</i>, no known <i>ROS1</i> alterations) who initiated 1L anti-PD(L)1-based combination therapy for mnsqNSCLC between 2017 and 2021. Kaplan-Meier analyses were used to assess overall survival (OS), time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after 1L initiation.</p><p><strong>Results: </strong>Overall, 142 physicians contributed deidentified data from 430 patients' medical charts. The distribution of PD-L1 expression levels was 31.2% with tumor proportion score (TPS) <1%, 42.3% with TPS 1%-49%, and 26.5% with TPS ≥50%. In 1L, patients received anti-PD(L)1 + chemotherapy (84.6%), anti-PD(L)1 + anti-CTLA4 with or without chemotherapy (11.9%), and anti-PD(L)1 + chemotherapy + anti-vascular endothelial growth factor receptor (3.5%). The median OS was 21.7 months (TPS <1%: 18.3 months; TPS 1%-49%: 21.6 months; TPS ≥50%: 24.0 months). The median TTD was 11.0 months (TPS <1%: 9.1 months; TPS 1%-49%: 10.9 months; TPS ≥50%: 12.2 months). The median rwPFS was 11.2 months (TPS <1%: 9.3 months; TPS 1%-49%: 11.1 months; TPS ≥50%: 13.2 months).</p><p><strong>Conclusion: </strong>This study assessed the real-world clinical effectiveness of 1L anti-PD(L)1-based combination therapy for mnsqNSCLC. Results from this study were generally consistent with previous clinical trials and published real-world evidence in 1L mnsqNSCLC.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400138"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Patterns and Health Care Resource Utilization of Patients With Non-Small Cell Lung Cancer in Puerto Rico: The TREATLINES-ONCOLUNG Study. 波多黎各非小细胞肺癌患者的治疗模式和医疗资源利用情况:TREATLINES-ONCOLUNG研究》。
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.1200/GO.24.00089
Edgar I Miranda, Axel Gierbolini-Bermúdez, Rafael Quintana, Carlos R Torres-Cintrón, Karen J Ortiz-Ortiz

Purpose: Lung cancer remains one of the leading causes of cancer-related mortality worldwide. It is the third cause of death among patients with cancer in Puerto Rico (PR) and non-small cell lung cancer (NSCLC) is the most prevalent. This study aims to describe the first-line treatment (1LT) and health care resource utilization (HCRU) among patients with NSCLC in PR.

Methods: A retrospective cohort study was conducted using the PR Central Cancer Registry Health Insurance Linkage Database to describe patients with NSCLC from 2012 to 2016. It describes sociodemographic and clinical characteristics on the basis of stage and histology and includes 1LT patterns and HCRU.

Results: A total of 1,011 patients met the inclusion criteria. Most were male (57.1%), married (54.1%), and had no comorbidities (55.8%). A significant proportion of patients (71.1%) were diagnosed at stages III and IV, with nonsquamous cell carcinoma being the most prevalent histology group (75.9%). About 61.7% received systemic therapy, 36.7% received radiotherapy, and 21.9% underwent surgery. Platinum (Pt)-based combinations were the most common 1LT (82.9%). On average, patients had 4.7 emergency room visits, nearly six hospitalizations, and 22.4 outpatient visits annually. The mean frequencies of positron emission tomography, ultrasounds, computerized tomography scans, and magnetic resonance imaging were 0.95, 0.11, 4.88, and 0.91, respectively.

Conclusion: To our knowledge, this study provides the first description of 1LT patterns, HCRU, and sociodemographic information among patients with NSCLC in PR. A significant number of patients were diagnosed at stage III or higher and received Pt-based systemic therapy as their 1LT. More research is required to investigate treatment patterns beyond the 1LT and to gain a comprehensive understanding of optimal care interventions and factors associated with early NSCLC diagnosis.

目的:肺癌仍然是全球癌症相关死亡的主要原因之一。在波多黎各(PR),肺癌是癌症患者的第三大死因,而非小细胞肺癌(NSCLC)是最常见的癌症。本研究旨在描述波多黎各非小细胞肺癌患者的一线治疗(1LT)和医疗资源利用(HCRU)情况:这项回顾性队列研究使用了PR中央癌症登记健康保险链接数据库,以描述2012年至2016年NSCLC患者的情况。研究以分期和组织学为基础,描述了社会人口学和临床特征,包括 1LT 模式和 HCRU:共有1011名患者符合纳入标准。大多数患者为男性(57.1%)、已婚(54.1%)、无合并症(55.8%)。很大一部分患者(71.1%)被诊断为 III 期和 IV 期,非鳞癌是最常见的组织学类型(75.9%)。约 61.7% 的患者接受了全身治疗,36.7% 接受了放射治疗,21.9% 接受了手术治疗。以铂(Pt)为基础的联合疗法是最常见的 1LT 疗法(82.9%)。患者平均每年看 4.7 次急诊、近 6 次住院和 22.4 次门诊。正电子发射断层扫描、超声波检查、计算机断层扫描和磁共振成像的平均频率分别为 0.95、0.11、4.88 和 0.91:据我们所知,这项研究首次描述了 PR NSCLC 患者的 1LT 模式、HCRU 和社会人口学信息。相当多的患者被诊断为 III 期或以上,并在 1LT 期间接受了以 Pt 为基础的全身治疗。我们需要开展更多的研究来调查1LT以外的治疗模式,并全面了解最佳护理干预措施以及与早期NSCLC诊断相关的因素。
{"title":"Treatment Patterns and Health Care Resource Utilization of Patients With Non-Small Cell Lung Cancer in Puerto Rico: The TREATLINES-ONCOLUNG Study.","authors":"Edgar I Miranda, Axel Gierbolini-Bermúdez, Rafael Quintana, Carlos R Torres-Cintrón, Karen J Ortiz-Ortiz","doi":"10.1200/GO.24.00089","DOIUrl":"10.1200/GO.24.00089","url":null,"abstract":"<p><strong>Purpose: </strong>Lung cancer remains one of the leading causes of cancer-related mortality worldwide. It is the third cause of death among patients with cancer in Puerto Rico (PR) and non-small cell lung cancer (NSCLC) is the most prevalent. This study aims to describe the first-line treatment (1LT) and health care resource utilization (HCRU) among patients with NSCLC in PR.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the PR Central Cancer Registry Health Insurance Linkage Database to describe patients with NSCLC from 2012 to 2016. It describes sociodemographic and clinical characteristics on the basis of stage and histology and includes 1LT patterns and HCRU.</p><p><strong>Results: </strong>A total of 1,011 patients met the inclusion criteria. Most were male (57.1%), married (54.1%), and had no comorbidities (55.8%). A significant proportion of patients (71.1%) were diagnosed at stages III and IV, with nonsquamous cell carcinoma being the most prevalent histology group (75.9%). About 61.7% received systemic therapy, 36.7% received radiotherapy, and 21.9% underwent surgery. Platinum (Pt)-based combinations were the most common 1LT (82.9%). On average, patients had 4.7 emergency room visits, nearly six hospitalizations, and 22.4 outpatient visits annually. The mean frequencies of positron emission tomography, ultrasounds, computerized tomography scans, and magnetic resonance imaging were 0.95, 0.11, 4.88, and 0.91, respectively.</p><p><strong>Conclusion: </strong>To our knowledge, this study provides the first description of 1LT patterns, HCRU, and sociodemographic information among patients with NSCLC in PR. A significant number of patients were diagnosed at stage III or higher and received Pt-based systemic therapy as their 1LT. More research is required to investigate treatment patterns beyond the 1LT and to gain a comprehensive understanding of optimal care interventions and factors associated with early NSCLC diagnosis.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400089"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathologic Characteristics Influencing Overall Survival of Patients With Early- Versus Average-Onset Colorectal Cancer at a Tertiary Care Center in Indonesia. 影响印度尼西亚一家三级医疗中心早发与平均发病结直肠癌患者总生存率的临床病理特征
IF 3.2 Q2 ONCOLOGY Pub Date : 2024-09-01 Epub Date: 2024-10-03 DOI: 10.1200/GO.24.00188
Susanna Hilda Hutajulu, Daniel Howdon, Yasjudan Rastrama Putra, Susanti Susanti, Didik Setyo Heriyanto, Naomi Yoshuantari, Adeodatus Yuda Handaya, Bambang Purwanto Utomo, Sri Retna Dwidanarti, Johan Kurnianda, Aru Wisaksono Sudoyo, Mohammad Ilyas, Matthew John Allsop

Purpose: There has been a global increase in early-onset colorectal cancer (EOCRC), yet there has been very limited exploration of its impact in Indonesia. This study aimed to determine the clinicopathologic characteristics and the overall survival (OS) of EOCRC compared with those of average-onset colorectal cancer (AOCRC).

Methods: Medical records were retrospectively reviewed from all patients presenting with colorectal cancer (CRC) at Dr Sardjito General Hospital (Yogyakarta, Indonesia) between 2016 and 2019. Sociodemographic, clinicopathologic, and treatment variables were extracted. t Tests were used to compare characteristics of EOCRC and AOCRC patient groups. The Cox proportional hazards regression model was used to analyze age and other potential prognostic factors.

Results: The total population (N = 1,276) comprised EOCRC (n = 149; 11.7%) and AOCRC (n = 1,127; 88.3%) patients. EOCRC patients were more likely to have a higher education level, be single, have out-of-pocket insurance, be underweight, and have signet ring histology (all P values <.05), compared with AOCRC patients. EOCRC and AOCRC groups had a comparable estimated 5-year OS of 34.2% and 36.9%, respectively. In multivariable analyses, performance status (Eastern Cooperative Oncology Group), hemoglobin level, cancer stage, and treatment intention were independent prognostic factors for OS (all P values <.05).

Conclusion: To our knowledge, this first major study of EOCRC in Indonesia highlights its role in the overall burden of CRC and its connection with social determinants of health. Patients with EOCRC are more commonly underweight and generally have a higher proportion of signet ring histology than AOCRC, yet OS in both groups is similar. Future research is required to identify risk factors to inform the content and focus of public health education activities, alongside delineating the biology and causes of early and average onset of the disease.

目的:早发结直肠癌(EOCRC)在全球呈上升趋势,但在印度尼西亚对其影响的研究却非常有限。本研究旨在确定早发性结直肠癌(EOCRC)与普通早发性结直肠癌(AOCRC)的临床病理特征和总生存率(OS):方法:对2016年至2019年期间在Dr Sardjito综合医院(印度尼西亚日惹)就诊的所有结直肠癌(CRC)患者的病历进行回顾性研究。采用 t 检验比较 EOCRC 和 AOCRC 患者组的特征。Cox比例危险回归模型用于分析年龄和其他潜在预后因素:总人数(N = 1,276)包括 EOCRC(n = 149;11.7%)和 AOCRC(n = 1,127;88.3%)患者。EOCRC患者更有可能受教育程度较高、单身、有自费保险、体重过轻、组织学为标志环(所有P值均为P值 结论:EOCRC患者更有可能受教育程度较高、单身、有自费保险、体重过轻、组织学为标志环:据我们所知,这是印尼首次对 EOCRC 进行大规模研究,研究强调了 EOCRC 在整个 CRC 负担中的作用及其与健康的社会决定因素之间的联系。与AOCRC相比,EOCRC患者体重偏轻的情况更为普遍,且标志环组织学比例通常更高,但两组患者的OS相似。未来的研究需要确定风险因素,以便为公共健康教育活动的内容和重点提供信息,同时明确早期和一般发病的生物学特征和原因。
{"title":"Clinicopathologic Characteristics Influencing Overall Survival of Patients With Early- Versus Average-Onset Colorectal Cancer at a Tertiary Care Center in Indonesia.","authors":"Susanna Hilda Hutajulu, Daniel Howdon, Yasjudan Rastrama Putra, Susanti Susanti, Didik Setyo Heriyanto, Naomi Yoshuantari, Adeodatus Yuda Handaya, Bambang Purwanto Utomo, Sri Retna Dwidanarti, Johan Kurnianda, Aru Wisaksono Sudoyo, Mohammad Ilyas, Matthew John Allsop","doi":"10.1200/GO.24.00188","DOIUrl":"https://doi.org/10.1200/GO.24.00188","url":null,"abstract":"<p><strong>Purpose: </strong>There has been a global increase in early-onset colorectal cancer (EOCRC), yet there has been very limited exploration of its impact in Indonesia. This study aimed to determine the clinicopathologic characteristics and the overall survival (OS) of EOCRC compared with those of average-onset colorectal cancer (AOCRC).</p><p><strong>Methods: </strong>Medical records were retrospectively reviewed from all patients presenting with colorectal cancer (CRC) at Dr Sardjito General Hospital (Yogyakarta, Indonesia) between 2016 and 2019. Sociodemographic, clinicopathologic, and treatment variables were extracted. <i>t</i> Tests were used to compare characteristics of EOCRC and AOCRC patient groups. The Cox proportional hazards regression model was used to analyze age and other potential prognostic factors.</p><p><strong>Results: </strong>The total population (N = 1,276) comprised EOCRC (n = 149; 11.7%) and AOCRC (n = 1,127; 88.3%) patients. EOCRC patients were more likely to have a higher education level, be single, have out-of-pocket insurance, be underweight, and have signet ring histology (all <i>P</i> values <.05), compared with AOCRC patients. EOCRC and AOCRC groups had a comparable estimated 5-year OS of 34.2% and 36.9%, respectively. In multivariable analyses, performance status (Eastern Cooperative Oncology Group), hemoglobin level, cancer stage, and treatment intention were independent prognostic factors for OS (all <i>P</i> values <.05).</p><p><strong>Conclusion: </strong>To our knowledge, this first major study of EOCRC in Indonesia highlights its role in the overall burden of CRC and its connection with social determinants of health. Patients with EOCRC are more commonly underweight and generally have a higher proportion of signet ring histology than AOCRC, yet OS in both groups is similar. Future research is required to identify risk factors to inform the content and focus of public health education activities, alongside delineating the biology and causes of early and average onset of the disease.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400188"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JCO Global Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1